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Abstract
Despite paclitxael’s clinical success, treating hormone-refractory breast cancer remains challenging. Paclitaxel has a poor
pharmacological profile, characterized by a low therapeutic index (TIX) caused by severe dose limiting toxicities, such as
neutropenia and peripheral neuropathy. Consequently, new drugs are urgently required. STX140, a compound previously
shown to have excellent efficacy against many tumors, is here compared to paclitaxel in three translational in vivo breast
cancer models, a rat model of peripheral neuropathy, and through pharmacological testing. Three different in vivo mouse
models of breast cancer were used; the metastatic 4T1 orthotopic model, the C3(1)/SV40 T-Ag model, and the MDA-MB-231
xenograft model. To determine TIX and pharmacological profile of STX140, a comprehensive dosing regime was performed
in mice bearing MDA-MD-231 xenografts. Finally, peripheral neuropathy was examined using a rat plantar thermal
hyperalgesia model. In the 4T1 metastatic model, STX140 and paclitaxel significantly inhibited primary tumor growth and
lung metastases. All C3(1)/SV40 T-Ag mice in the control and paclitaxel treated groups developed palpable mammary
cancer. STX140 blocked 47% of tumors developing and significantly inhibited growth of tumors that did develop. STX140
treatment caused a significant (P,0.001) survival advantage for animals in early and late intervention groups. Conversely, in
C3(1)/SV40 T-Ag mice, paclitaxel failed to inhibit tumor growth and did not increase survival time. Furthermore, paclitaxel,
but not STX140, induced significant peripheral neuropathy and neutropenia. These results show that STX140 has a greater
anti-cancer efficacy, TIX, and reduced neurotoxicity compared to paclitaxel in C3(1)/SV40 T-Ag mice and therefore may be of
significant benefit to patients with breast cancer.
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Introduction
Use of microtubule-targeting agents, such as the taxanes, to
treat early- and late-stage breast cancer is now common. However,
taxane efficacy is compromised by dose-limiting toxicities such as
neutropenia and neurotoxicity. Hypersensitivity reactions are also
triggered by the presence of non-ionic surfactant, CremophorH
EL, required in taxane formulations [1]. These factors result in
poor physiological tolerance, and optimal anti-tumor doses can
only be administered intermittently. Consequently, patients on
taxane therapy require frequent treatment holidays which allows
tumor regrowth and taxane resistance to develop. Although there
has been some success in developing new taxane analogs, notably
nab-paclitaxel and cabazitaxel, recent strategies aimed at lowering
taxane associated toxicities have shown only limited success [2].
Therefore, there remains an unmet clinical requirement for
compounds with both excellent efficacy against breast cancer and
a reduced toxicity profile.
One such compound is STX140 (2-methoxyestradiol-bis-sulfa-
mate; Figure 1) which shows oral efficacy against a range of in vitro
cancer cell lines and in vivo xenograft tumor models [3–16]. Our
previous work demonstrates that in breast cancer cells STX140, as
measured by tubulin binding assays [4] and as observed in MCF-7
cells using immunohistochemistry [17], causes microtubule
disruption and therefore tubulin destabilisation. This disruption
results in elevated cell cycle arrest [4], mitochondrial uncoupling
[11], release of cytochrome c [11], increased cyclin B1 expression
[8], and phosphorylation of Bcl-2 [13], all leading to significant
increases in cellular apoptosis. Therefore, STX140 and paclitaxel
both target cell cycle mechanics by disrupting tubulin. Further-
more, STX140 also inhibits in vitro and in vivo tumor angiogenesis
[6,10], and has excellent oral bioavailability (at 87%) [7,14,15].
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Furthermore, this compound is active in vivo against taxane-
resistant breast cancer [13], and its efficacy in vitro is not impaired
by known clinical mechanisms of resistance, such as the P-
glycoprotein pump [13], BCRP [13], and bIII tubulin over-
expression [17].
Here we compare STX140 efficacy with the taxane, paclitaxel,
in C3(1)/SV40 T/t-antigen transgenic mice bearing hormone-
independent breast cancer. This model recapitulates important
histopathological and molecular alterations observed in human
mammary cancer development over a highly predictable time-
course [18]. Therefore, this approach has significant advantages
over xenograft models, which have been much criticised over their
failure to provide accurate predictions of drug efficacy in clinical
trials [19,20] Furthermore, C3(1)/SV40 T/t-antigen mice have
been used extensively for the pre-clinical evaluation of anti-cancer
agents [21–25]. To prepare for Phase I trials, we also investigate
the toxicological and neuropathic profile of STX140 compared to
paclitaxel in a mouse model of peripheral neuropathy. Finally, we
determine STX140’s therapeutic index (TIX), a key measurement
to determine this compounds therapeutic window in clinical trials.
Materials and Methods
Ethics statement
Animals were housed according to local animal care protocols
at Imperial College London, U.K. and at Ipsen, France, and
complied with each countries animal welfare policies. Protocols for
studies were approved by a UK Home Office Licence (PPL 70/
6822). Animals lived on a 12:12 hr light-dark cycle at 22uC, with
access to food and water ad libitum. To limit suffering and for
ethical reasons, in all studies animals were removed if total tumor
mean diameter exceeded 15 mm, as recommended by Workman
et al. [26].
Compounds and materials
Details of the synthesis of STX140 have been published
elsewhere [9]. Micronized STX140 was prepared in 0.5% methyl
cellulose (MC; 400 cP). All other materials and medium were
obtained from Sigma-Aldrich, U.K. unless otherwise stated.
Cell culture
MDA-MB-231 cells and 4T1 mouse mammary cancer cells
from the American Type Culture Collection (LGC Promochem,
Teddington, U.K.) were grown in 10% foetal calf serum
supplemented RPMI-1640 medium.
Animals
Female athymic MF-1 mice aged 6–8 weeks were purchased
from Harlan, UK. NCr-nude mice aged 6–8 weeks were
purchased from Charles River, France. C3(1)/SV40 T/t-antigen
heterozygous transgenic mice in the FVB/N background were
bred from cryopreserved embryos obtained from the Jackson
Laboratory (Maine, U.S.A.). Using tail snips mice were genotyped
with primers for T-Ag:
59-CAGAGCAGAATTGTGGAGTGG-39, and
59-ACAAACCACAACTAGAATGCAGTG-39
Only female mice heterozygous for the C3(1)/SV40T-Ag
transgene were used.
Orthotopic 4T1 metastatic mouse model
STX140 and paclitaxel efficacy on metastatic tumor growth was
assessed using the well characterised 4T1 cell mouse model [27].
4T1 cells (2.56106) were inoculated into mammary fat pads of
athymic MF-1 female mice. Once primary tumors had reached
100 mm3 animals were divided into three groups of ten: vehicle
control (100 ml 0.5% MC p.o. five times weekly), STX140
(20 mg/kg p.o. five times weekly), and paclitaxel (15 mg/kg i.v.
twice weekly). Using electronic callipers, tumor measurements
were taken twice weekly and animal weights once weekly. Tumor
volume (V) was calculated using the formula: (length6width2/2).
Mice were culled 21 days after start of dosing and blood (via
cardiac puncture), lungs and livers collected to determine
circulating tumor cells (CTCs) and tissue metastasis.
Quantification of 4T1 CTCs and metastases
Blood. Triplicate 30 ml aliquots of heparinized whole blood
samples were mixed with 10% FBS in DMEM and plated in 6-well
plates in the presence of 60 mM 6-thioguanine (6-TG). This
selects for 4T1 cells as they are resistant to 6-TG-induced
apoptosis [27]. After 72 hours at 37uC, plates were washed twice
with HBSS, and cultured in 6-TG-supplemented 10% FBS in
DMEM for 96 hours.
Lung and Liver. Freshly isolated livers were washed in
HBSS, finely minced in 2 mg/ml filter-sterilized Collagenase I,
and then placed at 37uC in 2 mg/ml Hyaluronidase for 20 min
with agitation. Fresh lungs were washed in HBSS and finely
minced in 5 IU elastase/1 mg/ml filter-sterilized Collagenase IV
in HBSS. Minced samples were incubated at 4uC for 60 min with
agitation. Lung and liver samples were then filtered through
70 mm nylon cell strainers (BD Falcon Cell Strainers; BD
Biosciences, Oxford, U.K.). These filtered solutions were centri-
fuged at 1000 g for 5 min, the pellets washed with HBSS, re-
suspended in 10% FBS in DMEM containing 60 mM TG, and
aliquotted into 6-well plates (3 ml/well, 6 wells/sample). Plates
were then placed in a 37uC incubator for 7 days.
After 7 days, plated 4T1 cells were incubated with methanol for
5 minutes and then stained with 0.04% Giemsa solution. 4T1 cell
growth was quantified by scanning the stained plates using a
UMAX Astra 4000U scanner (Umax UK Ltd., Milton Keynes,
U.K.), and analyzing the mean intensity of the stain in each well
using Kodak 1D software (Kodak Ltd., Hemel Hempstead, U.K.).
Clonogenic metastases were calculated on a per-organ basis as an
average mean intensity per well.
C3(1)T-Ag Transgenic mouse studies and experimental
scheduling
At 5 weeks of age, C3(1)T-Ag mice were randomly assigned into
four separate groups: Control vehicle treated (0.5% MC p.o. daily,
n = 15); Early intervention (dosing started at 12 weeks of age)
STX140 (20 mg/kg/d, p.o., n = 15) and paclitaxel (15 mg/kg
twice weekly i.v., n = 8); Late intervention (dosing started when
tumor burden was greater than 100 mm3, approximately 20 weeks
of age) STX140 (20 mg/kg/d, p.o. n= 10). For clarity, this
treatment regiment is shown in Figure 2.
Mammary tumor measurements and body weights were taken
weekly. Tumor size was measured using electronic callipers, and
the tumor volume (V) calculated as previously mentioned. When
Figure 1. The chemical structure of STX140.
doi:10.1371/journal.pone.0080305.g001
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animals presented with multiple tumors, volumes were added
together to give total tumor burden. Mice were sacrificed if tumor
burden reached greater than 2000 mm3 or if animals lost over
10% body weight.
Peripheral Neuropathy
Determining mouse hind-paw thermal hyperalgesia is a well
established method to measure drug induced peripheral neurop-
athy [28]. This method exposes the lateral plantar surface of the
hind paw to a beam of radiant heat through a transparent Perspex
surface using a plantar analgesia meter for paw stimulation [29].
Withdrawal latency to the heat stimulus is recorded for both left
and right hind paws as the time taken from the onset of the
thermal stimulus to withdrawal of the hind paw from the heat
source. For each MF-1 female nude mouse, heat stimulation was
repeated three times with an interval of 3 minutes between
readings. Studies were performed double-blind. Animals were split
into three groups of twelve: Vehicle (0.5% MC, p.o. daily),
STX140 (20 mg/kg, p.o. daily), and paclitaxel (15 mg/kg, i.v.
twice weekly) and withdrawal latencies measured twice weekly. At
the end of the study, cardiac punctures were performed on all
animals and circulating leukocyte counts ascertained via flow
cytometry.
Therapeutic Index (TIX) and PK analysis
MDA-MB-231 breast cancer cells were implanted (56106 cells/
animal) s.c. into female NCr-nude mice on day 1. Once tumors
reached a mean of 100 mm3, animals were randomly assigned to
different groups to receive STX140 doses (10–80 mg/kg) and
schedules (daily or intermittently, i.e. thrice weekly). STX140 was
administered orally in 0.5% MC. Tumor volumes and body
weights were recorded weekly. Blood samples were taken via tail
vein bleeds on day 1 and day 28 of treatment for PK analysis.
AUC was measured based on STX140 plasma levels. TIX was
calculated based on first active and first toxic doses and the
respective related exposures.
To determine compound neurotoxicity, female nude mice
received either daily oral treatment with STX140 at the indicated
doses or i.v. paclitaxel at 15 mg/kg twice weekly. At the end of the
treatment period (day 43) or when the animals were found
moribund, sciatic nerve, brain and lumbar region of the spinal
cord were taken for anatomopathological analyses. Tissues were
paraffin embedded, sectioned and H&E stained. Pathological
assessment was performed by a professional anatomopathologist.
Statistical Analysis
One-way ANOVA followed by a Bonferroni’s multiple com-
parison test was performed to determine statistical significance
where applicable. Where only two groups are compared a
Student’s t test was applied. All values are represented as the
mean 6 standard error of the mean (SEM). For all survival data
the difference in the survival distributions of two samples was
determined using the Mantel-Cox test.
Results
STX140 and paclitaxel inhibit 4T1 xenograft tumor
growth and metastasis
Control tumors developed rapidly and were 15726220 mm3 at
day 17 post-inoculation. STX140 and paclitaxel significantly
(P,0.05) inhibited primary orthotopic mammary tumor growth
(Fig. 3A) with no effect on mouse weights (not shown). At day 17,
Figure 2. Experimental design for the use of STX140 and paclitaxel in vivo in C3(1)/SV40 Tag transgenic mice. Two different studies
were performed. In the early intervention study, animals were treated at 12 weeks of age for 15 weeks; mice were euthanized if tumor length reached
1.5 cm in any direction. The late intervention experiment was initiated when the tumor burden was greater than 100 mm3 and dosing of STX140 was
continuous until humane endpoints reached.
doi:10.1371/journal.pone.0080305.g002
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blood samples, liver and lung tissue were collected to assess plasma
CTC levels and metastatic lesions. Upon dissection lungs were
observed to contain numerous cancerous lesions. There were
significantly more metastatic lesions (p,0.01) in vehicle treated
animals compared to STX140 and paclitaxel treatment (Fig. 3B).
Digestion and culturing cells from lung tissue, with selection for
6-TG-resistant 4T1 colonies, also demonstrated a reduction in
the number of lung metastases as a result of STX140 and
paclitaxel treatment compared to control (Fig. 3C). This
reduction was also observed in CTCs. Figure 3D shows the
number of colonies that formed from 30 ml of blood after 10
days culture in 6-TG.
STX140 and paclitaxel in the C3(1)/T-Ag transgenic
mouse
Experimental schematics for these studies are shown in Figure 2.
The early intervention study assessed STX140 efficacy against
paclitaxel in this model. Unfortunately, not enough heterozygous
C3(1)/SV40 T/t-antigen mice were bred to compare STX140
against paclitaxel in the late intervention arm.
Early Intervention
Palpable mammary tumors were evident after 14 weeks and all
animals in the control group presented with malignancies by the
23rd week of age. Figure 4A shows that the onset of palpable
tumors was significantly attenuated by STX140 (P,0.001), but
not paclitaxel. Similar to the control group, paclitaxel-treated
animals all developed mammary carcinoma by the 23rd week. In
contrast, in 47% of mice treated at week 12 onwards with
STX140, no palpable tumors were observed throughout the study.
In vehicle-treated animals, mammary cancer growth was first
observed at 17 weeks of age. Cumulative tumor burden reached
1556.66289.8 mm3 by week 25. Tumor growth rate, shown in
Figure 4B, was initially significantly inhibited by both STX140
and paclitaxel (P,0.001). However, by week 23, paclitaxel
treatment did not significantly reduce total tumor burden (at
519.76280.6 mm3) compared to controls (at 829.96222.6 mm3).
In mice that did develop malignancy, mammary tumor growth
was significantly (P,0.001) inhibited with STX140 treatment
throughout the treatment period (weeks 12–25), reaching a
cumulative tumor burden volume of 852.96425 mm3 at week 25.
To manage and reduce animal suffering, once animals had
either lost 10% of their body weight or tumor burden exceeded
2000 mm3, they were humanely culled and survival data
calculated (Figures 4C and 4D). All vehicle treated mice were
terminated by the 27th week of age. This was due exclusively to
excessive tumor burden. Paclitaxel treatment had no effect on
animal survival, with all animals removed from the study by week
27. In contrast, STX140 dosing (p.o. daily from weeks 12–27)
resulted in significantly prolonged survival rates (P = 0.0316) with
43% of animals having no observable tumors throughout the
study.
Figure 3. The effect of STX140 (20 mg/kg/daily p.o.) and paclitaxel (15 mg/kg/twice weekly i.v.) on 4T1 orthotopic tumor growth
and metastasis. A) STX140 and paclitaxel inhibit primary mammary carcinoma growth. B) Counts of the number of metastatic lesions on the lungs
of animals treated with STX140 and paclitaxel. C) 4T1 colonies cultured from the lungs of these mice. D) 4T1 colonies cultured from the blood of mice
bearing 4T1 mammary tumors. Data represent mean 6 s.e.m. * P,0.05, ** P,0.01, *** P,0.001 compared to controls. n = 8/group.
doi:10.1371/journal.pone.0080305.g003
Paclitaxel and STX140 in Breast Cancer
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Late intervention
Mice bearing tumors at 100–300 mm3 were treated with
20 mg/kg/d STX140 for 8 weeks (unless tumor burden reached
over 2000 mm3 at which point animals were euthanized). Results
are shown in Figure 4E. At the start of the experiment there was a
non-significant difference in tumor size between the vehicle and
STX140 treated animals (236.76108.4 mm3 compared to
107.8640.3 mm3). Three weeks dosing with STX140 resulted in
a significant 80.4% reduction in tumor growth compared to
controls and this reduction was 35.0% (P,0.05) after 7 weeks.
Animals receiving STX140 demonstrated a small but significant
(P,0.0034) survival advantage of 1–2 weeks compared to control
animals (Figure 4F).
TIX, PK profile, and neurotoxicity of STX140
In mice bearing MDA-MB-231 xenografts, four of the
administered doses of STX140 (40, 35, 30, and 25 mg/kg/d)
induced tumor regression (Fig. 5A). All daily dosing regimens
(10–40 mg/kg) showed some efficacy (with an ED50 of 10 mg/
kg/d), with 30 mg/kg/d being the lowest dose causing
mortality (1 death in 21 mice), although 25 mg/kg/d did
result in initial substantial weight loss (Fig. 5B). As the highest
dose of STX140 (40 mg/kg/d) did not result in a 50%
mortality rate, LD50 could not be ascertained. However, as
52.3% of mice treated with 30 mg/kg/d STX140 lost over
10% body weight, we have used this parameter as our LD50
marker.
Figure 4. The effect of STX140 (20 mg/kg/daily p.o.) and paclitaxel (15 mg/kg/twice weekly i.v.) on tumor development in C3(1)/
SV40 T-Ag mice. A) Palpable tumors developed in all control and paclitaxel treated animals, but not in the STX140 treated group. B) When
administered at 12 weeks of age (early intervention), STX140 inhibited development of the overall tumor burden throughout the study. C) and D)
STX140, not paclitaxel, treatment (early intervention) gave a significant survival advantage to C3(1)/SV40 T-Ag mice. E) During the late intervention
stage of the study, treatment with STX140 commenced when tumor burden was greater than 100 mm3. STX140 reduced tumor burden in these
animals and F) conferred a significant survival advantage. Data represent mean 6 s.e.m. * P,0.05, ** P,0.01, *** P,0.001 compared to controls.
n = 10–15/group.
doi:10.1371/journal.pone.0080305.g004
Paclitaxel and STX140 in Breast Cancer
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Figure 5. The spectrum of STX140 anti-cancer efficacy in mice bearing MDA-MB-231 breast cancer xenografts. Two dosing regimens
were employed, daily (panels A and B), and thrice weekly (panels C and D). A) Daily dosing of STX140 was significantly efficacious at 10 mg/kg and
caused animal mortality at 30 mg/kg. B) Animals treated with 40, 35, and 30 mg/kg initially showed signs of significant weight loss, although this
response was not seen in all animals hence the apparent recovery throughout the study. C) Thrice weekly dosing of STX140 was significantly
Paclitaxel and STX140 in Breast Cancer
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On the intermittent schedule one dose induced MDA-MB-231
tumor regression (80 mg/kg thrice weekly, Fig. 5C, with an ED50
of 20 mg/kg thrice weekly), and this dosing regimen was better
tolerated with less toxicity in terms of body weight loss and animal
mortality (Fig. 5D). Using similar reasoning as mentioned above,
we calculated the LD50 as 80 mg/kg thrice weekly. Consequently,
TIX was calculated (LD504ED50) as:
Daily dosing over 28 daysð Þ{30710~TIX of 3
Thrice weekly dosing over 28 daysð Þ{80720~TIX of 4
In terms of PK, no plasma accumulation of STX140 was
observed, even after 28 days of continuous daily oral treatment
(Fig. S1). No clear dose-proportionality could be observed (Fig. 5E),
rather a 3 phase PK behavior with a first phase of dose-
proportional increase between 10 and 20 mg/kg, then a second
phase with a plateau (25 to 40 mg/kg) and finally a third phase
with a trend to dose-dependent increase (40–80 mg/kg).
In neurotoxicity studies, paclitaxel demonstrated neurotoxic
effect in both experiments, showing axonal degeneration in the
sciatic nerves, minimal to mild degeneration within the white
matter of the dorsal funiculus of the lumbar spinal cord (Table 1).
In contrast, anatomopathological analyses of sciatic nerves, brain
and lumbar region of the spinal cord of nude mice treated with
STX140 revealed that, even at toxic doses, no lesions were
observed, suggesting limited neurotoxic effect.
We further investigated STX140 neurotoxicity profile com-
pared to paclitaxel using a thermal hyperalgesia method of
peripheral neuropathy. Average paw withdrawal latencies in
untreated animals was between 11–13 s (Fig. 6A). Daily treatment
of vehicle or STX140 (Fig. 6A and 6C) did not affect withdrawal
latency relative to day 0. However, animals treated twice weekly
with 15 mg/kg (i.v.) of paclitaxel demonstrated reduced paw
withdrawal latency (Fig. 6B). This significant neuropathy, at a
withdrawal latency of 9.461.8 s, developed after 14 days of
treatment (four paclitaxel doses). Furthermore, significant neutro-
penia was observed in blood samples obtained from paclitaxel
treated animals, but not in STX140 treated mice (Fig. 6D).
Discussion
Paclitaxel, despite possessing numerous toxicological challenges
and inducing drug-resistance, remains the drug of choice for many
oncologists. The early promise of overtly targeted therapies has yet
to be realised and where efficacy is seen this is usually in
combination with a well established cytotoxic regime. With new
sequencing studies revealing the degree of heterogeneity and
evolution occurring within individual tumours there is a new
emphasise for multi-targeted agents which may act with or replace
existing cytotoxic drugs [30]. Consequently, the identification of
new compounds effective against both early- and late-stage breast
cancer and have favourable toxicity profiles remains paramount to
advancing treatment. Therefore, this work aimed to: 1) compare
STX140 with paclitaxel on the growth, metastasis and survival
outcomes of two stages of mammary cancer development in two
different pre-clinically relevant mammary cancer mouse models
and: 2) determine whether STX140 possesses a favourable TIX
with an acceptable toxicity profile in regards to effects on axonal
degeneration and circulating leukocytes.
Our initial studies focused on the highly aggressive, metastatic
4T1 breast cancer model. STX140 showed similar efficacy to
paclitaxel, significantly reducing primary tumor growth and lung
and liver metastatic lesions. Furthermore, both compounds
reduced CTC numbers and metastatic tumor cells obtained from
lungs. This is the first time STX140 has been shown to be effective
at reducing metastasis, and therefore warranted moving this
compound forward into more clinically relevant breast cancer
models prior to Phase I studies.
Therefore, we next investigated STX140 efficacy in the C3(1)/
SV40 T-Ag mouse model of breast cancer. In the early
intervention arm, at 12 weeks of age when high-grade MIN
(similar to human ductal carcinoma in situ) had developed, mice
were treated with either STX140 or paclitaxel. In the STX140-
treated group, 43% of the animals did not develop tumors, and it
was only STX140 that significantly inhibited mammary cancer
growth. Unexpectedly, paclitaxel only had anti-proliferative effects
on early tumor growth, and no effect on blocking tumors
becoming physically palpable.
In the late intervention study only STX140 was investigated.
STX140 administered to animals with larger tumor burdens (100–
300 mm3) significantly reduced burden leading to an increased
survival outcome. These results are encouraging considering the
aggressive nature of these cancer models and indicate that
STX140 may provide clinical benefit to patients suffering from
both early- and late-stage breast cancer.
Previous research in C3(1)/SV40 T-Ag mice showed 150 mg/
kg/d 2-ME, of which STX140 is a derivative, also significantly
inhibited breast tumor growth [25]. However, in the early
intervention regimen, and in contrast to STX140, all 2-ME
treated animals developed mammary cancer. 2-ME is rapidly
inactivated in the gut by 17b-hydroxysteroid dehydrogenase type-
2 [31], this most likely accounting for its poor PK profile.
Consequently, high doses of 2-ME are required to maintain
efficacious plasma concentrations. In contrast, STX140 avoids
efficacious at 40 mg/kg, with mortality only observed at 80 mg/kg (1 out of 21 animals). D) Animals treated with 70 and 80 mg/kg STX140 showed
some weight loss, however only 1 reached the humane endpoint of a greater than 10% reduction in body weight. E) Plasma concentration, as
measured by AUC (ng/ml) of STX140 24 h after single dose. A three phase response is seen; firstly an initial dose-proportional increase (10–20 mg/kg),
a secondary plateau (20–40 mg/kg), followed by a tertiary trend toward a dose-proportional increase (40–80 mg/kg). Data represents mean6 s.e.m. *
P,0.05 compared to controls. n = 21/group.
doi:10.1371/journal.pone.0080305.g005
Table 1. Anatomopathological analysis of brain, spinal cord
and sciatic nerve from nude mice treated with STX140 or
paclitaxel.
Agent mg/kg Route Schedule Mortality Neurotoxic
none - - - No No
paclitaxel 30 iv qod65 No Yes
STX140 35 po qd610 Yes No
STX140 30 po qd67 Yes No
STX140 25 po qd611 No No
STX140 20 po qd624 No No
STX140 10 po qd628 No No
doi:10.1371/journal.pone.0080305.t001
Paclitaxel and STX140 in Breast Cancer
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first-pass metabolism and is readily detected in plasma after a
single 20 mg/kg oral dose [7], and this superior PK profile may
account for STX140 proving more effective in C3(1)/SV40 T-Ag
mice compared to 2-ME.
It is unclear why paclitaxel failed to completely inhibit
mammary cancer growth in the early intervention C3(1)/
SV40 T-Ag mouse study. To our knowledge, there are no
reports of paclitaxel use in C3(1)/SV40 T-Ag mice. As
paclitaxel was discovered and clinically developed prior to the
availability of transgenic mouse models, only a handful of
studies have examined its effects in these model systems. When
administered to TgMISIIR-TAg-DR26 transgenic mice that
develop spontaneous ovarian cancer, paclitaxel, in combination
with cisplatin, significantly reduced tumor burden [32].
Furthermore, paclitaxel alone inhibited the growth of retino-
blastoma in LH beta-Tag–positive mice [33]. Interestingly, in
our study, paclitaxel did inhibit growth from week 19 to 22 in
the early intervention arm of our study, with this inhibition
being lost from week 22 onwards. Due to known dose limiting
toxicities, as confirmed by our thermal hyperalgesia and
neutropenia studies and shown elsewhere [34,35], paclitaxel
was only administered intravenously twice weekly at 15 mg/kg.
This scheduling limits paclitaxel’s plasma availability, and
therefore tumor exposure time. Consequently, loss of efficacy
may be the result of taxane-resistance or the limited exposure
time may have compromised paclitaxel efficacy against the
aggressive disease seen in these animals. In contrast, tumor
growth continued to be suppressed by week 23 in STX140
treated animals, although after this time proliferation did
increase.
Previous studies have demonstrated the excellent efficacy of
STX140 against MDA-MB-231 xenografts [12,14]. However, the
TIX – vital to inform future clinical studies – of STX140 was
unknown. To determine this we performed a large ranging study
comprising of two dosing schedules – daily and thrice weekly – in
mice bearing MDA-MB-231 breast cancer xenografts. These
studies allowed for the determination of a TIX of 3 (for daily
dosing), and 4 (for weekly dosing). Previous research has identified
STX140 to have a maximum tolerated dose of 150 mg/kg (p.o.)
[13], in contrast to paclitaxel at 80 mg/kg [36].
In conclusion, this new data on STX140 activity demonstrat-
ed that it confers significant tumor reduction and survival
advantage to C3(1)/SV40 T-Ag mice with both early- and late-
stage carcinomas. Orthotopic mammary cancer growth was also
blocked by STX140 and paclitaxel, with both drugs inhibiting
lung 4T1 cell metastasis. In thermal hyperalgesia studies,
paclitaxel, but not STX140, increased animal paw withdrawal
latencies indicative of peripheral neuropathy. Furthermore,
STX140 possessed a TIX of 3–4, suggesting a compound with
favourably clinical application. As a prototype STX140 oral
Figure 6. The effects of STX140 and paclitaxel on thermal paw withdrawal latency in MF-1 female nude mice. A) Vehicle treated control
animals paw withdrawal did not alter throughout experiment. B) Twice weekly dosing of paclitaxel, by day 14, caused significant thermal
hyperalgesia. C) Daily dosing of STX140 did not significantly affect paw withdrawal latencies. D) Plasma neutropenia was evident in animals treated
with paclitaxel, but not with STX140. Data represents mean 6 s.e.m. ** P,0.01 compared to day 0 from the same group. n = 10/group.
doi:10.1371/journal.pone.0080305.g006
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tablet formulation has already been developed and tested in vivo
[14], this promising compound is now ready to be moved into
Phase I clinical trials for patients with hormone-independent
cancers.
Supporting Information
Figure S1 STX140 (given orally at 10, 20, 40, 80 mg/kg/
d) does not accumulate in mouse plasma after repeated
administration, as measured on day 1 and day 28 post
STX140 administration.
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